Clinuvel Pharmaceuticals Limited

There were no approved drugs for vitiligo until Opzelura got the green light in the US this summer but Australia's CLINUVEL PHARMACEUTICALS LIMITED is hoping that Scenesse, already marketed for a ra

Incyte Corporation reinvented itself as a dermatology company a few years ago and is building critical mass in that therapeutic area with the US approval on 18 July of Opzelura for vitiligo, less tha

New 52-week Phase III data for Incyte Corporation ’s topical JAK inhibitor Opzelura (ruxolitinib) for vitiligo show no new safety signals, despite lingering concerns about the safety and tolerability

Incyte Corporation will have a lot of room to grow within a vitiligo market that remains nascent and immature, with little in the way of therapy options for patients, thanks to the positive Phase III